Patent SG-11201407784U-A (SG)
Title: Engineered botulinum neurotoxin
Inventor: DONG MIN
IPC: C07K14/33
Filed: 2013-03-13
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date ^ ^ WO 2013/180799 A1 5 December 2013 (05.12.2013) WIPO I PCT (51) International Patent Classification: A61K38/48 (2006.01) C07K14/33 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/030737 13 March 2013 (13.03.2013) English English (30) Priority Data: 61/653,214 30 May 2012 (30.05.2012) US (71) Applicant: PRESIDENT AND FELLOWS OF HAR­ VARD COLLEGE [US/US]; 17 Quincy Street, Boston, MA 02138 (US). (72) Inventors; and (71) Applicants : STENMARK, Pal Erik Gustav [SE/SE]; Sergeantgrand 16, S-17743 Jarfalla (SE). BERNTSSON, Ronnie, Per-Arne [SE/SE]; Wedtorpsvagen 64, S-18434 Akersberga (SE). (72) Inventors: DONG, Min; 1 Pine Hill Drive, Southborough, MA 01772 (US). PENG, Lisheng; 1 Pine Hill Drive, Southborough, Massachusetts 01772 (US). (74) Agents: RESNICK, David et al.; Nixon Peabody LLP, 100 Summer Street, Boston, MA 02110-2131 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: ENGINEERED BOTULINUM NEUROTOXIN 0\ 0\ © 00 h-Sytll m-Syt II \fT/8 tan is: Input £1191 Ml WT E11S1W! S1199Y B1191SWS S11S9Y WT Gangl OisST/B rtriv + - + - + + - + i-H o CJ o & (57) Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-H), comprising c one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; El 1911; E1191Q; E1191T; S1199Y; S1199F; S1199L; SI 20 IV; or combina­ tions thereof. Specific combination mutations include El 191M and SI 199L, El 191M and 199Y, SI El 191M and 199F, SI El 191Q and SI 199L, El 191Q and 1199Y, S or E 1191 Q and 1199F. S Other substitution mutations are also disclosed. Isolated modified re­ ceptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.